Boston Scientific’s (BSX) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Boston Scientific (NYSE:BSX) in a report issued on Monday morning,Benzinga reports. They currently have a $97.00 price objective on the medical equipment provider’s stock.

A number of other equities analysts also recently commented on BSX. Truist Financial lowered their price objective on Boston Scientific from $95.00 to $92.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. JPMorgan Chase & Co. reduced their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Robert W. Baird lowered their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Finally, Mizuho dropped their price objective on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $104.36.

Boston Scientific Stock Down 1.2%

Boston Scientific stock opened at $62.01 on Monday. The firm has a market capitalization of $92.15 billion, a P/E ratio of 31.96, a P/E/G ratio of 0.97 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific has a twelve month low of $61.24 and a twelve month high of $109.50. The stock’s fifty day simple moving average is $75.78 and its 200-day simple moving average is $89.84.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the business posted $0.70 earnings per share. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Norges Bank acquired a new position in shares of Boston Scientific in the 4th quarter valued at $2,199,395,000. Parnassus Investments LLC raised its stake in Boston Scientific by 42,978.9% during the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after acquiring an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP raised its stake in Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after acquiring an additional 3,671,548 shares in the last quarter. Maverick Capital Ltd. purchased a new stake in Boston Scientific in the fourth quarter valued at $280,735,000. Finally, Jennison Associates LLC lifted its position in Boston Scientific by 133.5% in the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after acquiring an additional 2,823,744 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: CHAMPION‑AF trial met all primary and key secondary endpoints for the WATCHMAN FLX versus NOACs — clinical data supports the WATCHMAN franchise and stroke-prevention positioning, which is bullish for long-term device revenues. Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints
• Positive Sentiment: Boston Scientific completed its acquisition of Valencia Technologies — expands product pipeline/technology footprint (supports tuck‑in growth and cross‑sell opportunities). Boston Scientific completes Valencia Technologies acquisition
• Positive Sentiment: Additional clinical/data wins and study support for intravascular ultrasound (IVUS) in PCI underscore minimally invasive care leadership — a structural growth thesis for cardiovascular devices. Boston Scientific study backs use of intravascular ultrasound in PCI
• Neutral Sentiment: Some analysts reiterated positive views (RBC, Needham, Raymond James earlier reaffirmations), and long‑term bull pieces highlight durable growth — supports case for recovery if execution stabilizes. Boston Scientific (NYSE:BSX) Earns “Outperform” Rating from Royal Bank Of Canada
• Negative Sentiment: Raymond James downgraded the stock and cut estimates amid concerns about U.S. electrophysiology trends and Watchman uptake, which triggered a sharp share decline and hurt near‑term sentiment. Raymond James downgrades Boston Scientific but long-term story remains intact
• Negative Sentiment: Unusually large put‑option volume today (put buying jumped ~205%) signals elevated short‑term hedging or bearish bets from traders, adding downside pressure. Options activity report
• Negative Sentiment: Multiple law firms have filed or solicited investors for securities‑fraud class actions tied to allegations about disclosure of electrophysiology volumes and related issues — legal risk and potential litigation costs are headline negatives for sentiment. Bronstein class action notice

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.